✦ LIBER ✦

A comparison of ciprofibrate and sustained release bezafibrate in patients with type II hyperlipidaemia

✍ Scribed by D.J. Betteridge; G. O'Bryan-Tear; M.J. Tomlinson

Book ID: 118326221
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 103 KB
Volume: 115
Category: Article
ISSN: 0021-9150
DOI: 10.1016/0021-9150(95)96620-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of slow release bezafibrate on t

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

✍ Rovellini, A.; Sommariva, D.; Branchi, A.; Maraffi, F.; Montalto, C.; Gandini, R 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 520 KB

Efficacy and safety of a combination of

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

✍ Paolo Pauciullo; Carlo Borgnino; Rodolfo Paoletti; Mario Mariani; Mario Mancini 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Clinical trial of methyl clofenapate (A

Clinical trial of methyl clofenapate (A derivative of clofibrate) in patients with essential hyperlipidaemias: With special reference to type II (primary) hyperlipidaemia

✍ G.M. Craig; K.W. Walton 📂 Article 📅 1972 🏛 Elsevier Science 🌐 English ⚖ 637 KB

Double-blind comparison of etodolac sust

Double-blind comparison of etodolac sustained-release tablets and diclofenac sustained-release tablets in patients with rheumatoid arthritis: An interim report

✍ F. Porzio; M. Schattenkirchner 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 524 KB

Pharmacokinetics of Verapamil and Norver

Pharmacokinetics of Verapamil and Norverapamil in Patients with Hypertension: A Comparison of Oral Conventional and Sustained Release Formulations

✍ Jørgensen, N. P. ;Walstad, R. A. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

Effects of Naltrexone Sustained- Release

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

✍ Hollander, P.; Gupta, A. K.; Plodkowski, R.; Greenway, F.; Bays, H.; Burns, C.; 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 682 KB

## OBJECTIVE To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. ## RESEARCH DESIGN AND METHODS This was a 56-week, double-blind, placebo-cont